An interventional study of Videoconference Antimicrobial Stewardship Team in Common Infections, Urinary Tract Infections and Respiratory Tract Infections, sponsored by VA Office of Research and Development. Enrolling by invitation at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Other
Antimicrobial-resistant and healthcare-associated pathogens are a global health threat. The goals of antimicrobial stewardship are to minimize unnecessary and inappropriate antimicrobial use as a means to combat antimicrobial resistance. The interdisciplinary Videoconference Antimicrobial Stewardship Team (VAST) was initially developed and tested as a telehealth teleconferencing training and mentoring program in 2 rural pilot sites, then was extended to 9 rural sites, using telehealth to connect clinicians at a rural VAMC to a geographically distant infectious disease expert. Qualitative interviews showed that participants valued VAST and it improved patient care. This project will expand the VAST to other VAMCs and assess the VASTs' impact on antimicrobial prescribing. This work will directly increase access to antimicrobial stewardship consultation at rural VA facilities, which are often underserved by infectious disease expertise.
Background: Antimicrobial resistance (AMR) is a current pandemic. Access to ID physicians and pharmacists in VHA is limited and many VHA healthcare systems do not have an ID specialist. This gap in expertise is detrimental, as the presence of ID trained physicians and pharmacists in acute care is associated with improved antimicrobial utilization. Telehealth can facilitate antimicrobial stewardship in VA facilities underserved by ID expertise. The interdisciplinary Videoconference Antimicrobial Stewardship Team (VAST)consists of weekly meetings between an interdisciplinary team at a rural VAMC with an off-site ID trained physician and/or pharmacist who meet by videoconference. At each session, participants discuss patients receiving antibiotics or who may potentially receive antibiotics. Team members enter the VAST's recommendations into the electronic medical record (EMR) at the rural VAMC. The ID physicians capture their clinical effort by completing interfacility consults placed through the EMR. The aims of this hybrid effectiveness trial are to assess the implementation of VAST and antibiotic utilization outcomes.
Aim 1: Implement and evaluate the implementation of VAST, using an implementation playbook with external facilitation and tailoring. VAST will be implemented over 15 months, plus sustainability follow-up in 6 rural VAMCs using key implementation strategies of external facilitation provided by CARRIAGE, tailoring and adaptation of VAST, and use of an implementation playbook. Process maps (which informed the playbook) from the previous VAST expansion captured VAST experiences at each site and illuminated successful implementation processes, showing that tailoring and adapting the VAST program based on site-specific needs, individual clinical processes, and patient care needs was crucial to its success and sustainability. The playbook details the general process for setting up an e-consult VAST clinic and scheduling and conducting VAST sessions. Site-specific tailoring, adaptation, and facilitation of VAST will occur based on playbook information. CARRIAGE members will hold initial facilitation calls weekly with VASTs, with ad hoc support available as well. CARRIAGE will facilitate an initial kick off meeting via Teams for each VAST to encourage team building and expectations for the ensuing sessions.
Aim 2: Assess the impact of VAST on antimicrobial use and the care of Veterans with suspected and confirmed infections. Using a quasi-experimental design, the investigators will assess outcomes for new rural sites implementing VAST and for the current rural sites currently using VAST to assess sustainability. For each site, the investigators will calculate these statistics monthly for the 12 months prior to and 15 months following the first VAST session (allowing for a 3-month wash-in period), and up to 24 months to assess sustainability. The investigators will include a control group of rural sites not utilizing VAST (matched). Antibiotic use metrics including rates of total and broad-spectrum anti-biotic use, antibiotic starts, and length of antibiotic therapy will be evaluated. The primary outcome is days of antibiotic therapy per 1000 days of care (DOT/1000 DOC) to measure the overall rate of antibiotic use; key secondary outcomes include rate of broad-spectrum antibiotics, defined as agents with an Antibiotic Spectrum Index score of ≥ 8;72 rate of antibiotic starts, calculated as the number of new starts per 1000 DOC; and length of antibiotic therapy in days. Other outcomes may be evaluated including management of resistant infections including treatment selection. The investigators will use VA CDW/Millennium to obtain antimicrobial prescribing, diagnosis, comorbidity, microbiologic, laboratory, and demographic data.
779 studies on the registry are indexed under Urinary Tract Infections; 132 are open to participants now.
This study's planned enrollment of 6 is below the median of 130 across 544 interventional studies indexed under Urinary Tract Infections.
Browse Urinary Tract Infections studies →VA Office of Research and Development is the lead sponsor of 1,767 studies on the registry; 394 are open to participants now.
Of its 209 completed or terminated interventional studies of FDA-regulated products, 183 (88%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-VA medical centers without local ID expertise that pair with an ID-expert from another VA medical center
Exclusion Criteria:
-none
Sites that implement VAST
Other: Videoconference Antimicrobial Stewardship Team
Implementation of VAST in hybrid effectiveness trial. Sites that implement VAST will have outcomes measured before and after implementation of VAST. Implementation outcomes will be measured.
Also known as: VAST
Days of Antibiotic Therapy (DOT) / 1000 Bed Days of Care (DOC)
Days of antibiotic therapy per 1000 days of care (DOT/1000 DOC), measures the overall rate of antibiotic use and is a common metric that accounts for dose adjustments, including for people who receive dialysis. Administration of any dose of an antimicrobial on a given day represents a single DOT for that agent, regardless of the number of times the doses are administered or the dose strength.
Time frame: 2.25 years
Antibiotic Starts
The investigators will measure the rate of antibiotic starts (new prescriptions), calculated as the number of starts per 1000 DOC.
Time frame: 2.25 years
Rate of Broad-spectrum Antibiotics
The investigators will specifically examine the rate of broad-spectrum antibiotics, defining broad-spectrum agents as those with an Antibiotic Spectrum Index (ASI) score of 8. This scale ranges from 1 to 13; the ASIs for penicillin, doxycycline, ciprofloxacin, and ertapenem are 2, 5, 8 and 9, respectively.
Time frame: 2.25 years
Reach
Reach will be measured by the number of Veterans served or discussed during VAST sessions.
Time frame: 2 years
Adoption
Adoption will include the number of sessions completed by each VAST team, the number and description of attendee roles and practice settings, and the number of ID e-consults.
Time frame: 2.25 years
Implementation
Implementation will include the number and types of recommendations for a sample of VAST meetings, the proportion of those recommendations accepted, and documentation of tailoring/adaptations.
Time frame: 2 years
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
VA Office of Research and Development →